LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Rivaroxaban vs placebo for extended antithrombotic prophylaxis after laparoscopic surgery for colorectal cancer

Photo from wikipedia

Venous thromboembolism (VTE) is a common adverse event following surgery, with risks related to the nature of the surgery, the presence of cancer, and other comorbidities. In a randomized, double-blind,… Click to show full abstract

Venous thromboembolism (VTE) is a common adverse event following surgery, with risks related to the nature of the surgery, the presence of cancer, and other comorbidities. In a randomized, double-blind, placebo-controlled trial with patients having laparoscopic surgery for colorectal cancer, Becattini et al demonstrated that the addition of 3 weeks of rivaroxaban to 1 week of low molecular weight heparin reduces the relative risk of VTE by 73% without increasing the bleeding risk. This finding establishes a new standard of prophylaxis for this surgical scenario.

Keywords: surgery; surgery colorectal; placebo; colorectal cancer; laparoscopic surgery; cancer

Journal Title: Blood
Year Published: 2022

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.